# ğŸ§¬ In vivo CAR-T æ–‡çŒ®å‘¨æŠ¥

> ğŸ“… æ›´æ–°æ—¥æœŸ: 2026-01-14 | â±ï¸ ç»Ÿè®¡èŒƒå›´: è¿‡å» 7 å¤© | ğŸ” å…³é”®è¯: In vivo CAR-T

## ğŸ“˜ æœ€æ–°ç»¼è¿° (Reviews) - 2 ç¯‡
---
### [Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.](https://pubmed.ncbi.nlm.nih.gov/41513408/)
- ğŸ“š **Journal for immunotherapy of cancer** | ğŸŒŸ **IF: 10.9**
- **æ‘˜è¦**: Adoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has been hindered by multiple factors, including tumo...

### [Advancing Cancer Immunotherapy: Chimeric Antigen Receptor (CAR)-T Cell Engineering through Novel Screening Methods.](https://pubmed.ncbi.nlm.nih.gov/41490986/)
- ğŸ“š **Biomolecules & therapeutics** | IF: N/A
- **æ‘˜è¦**: Cancer immunotherapy represents a paradigm-shifting achievement in oncology. Particularly, chimeric antigen receptor (CAR)-T cell therapy utilizing genetically engineered T cells has produced remarkab...

## ğŸ”¬ æœ€æ–°ç ”ç©¶è®ºæ–‡ (Articles) - 12 ç¯‡
---
### [Single-Chain IL-23 Secretion by CAR T Cells Improves Tumor Control and Persistence Against Solid Tumors.](https://pubmed.ncbi.nlm.nih.gov/41520177/)
- ğŸ“š **Molecular therapy : the journal of the American Society of Gene Therapy** | IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor (CAR) T cell therapy achieves durable remissions in hematological malignancies, yet its success against solid tumors is blunted in part by the tumors' highly immunosuppressiv...

### [Clinical Trial Results Provide the Rationale to Protect Dual HIV-specific T Cells with a Signaling-Defective HIV Fusion Inhibitor.](https://pubmed.ncbi.nlm.nih.gov/41520175/)
- ğŸ“š **Molecular therapy : the journal of the American Society of Gene Therapy** | IF: N/A
- **æ‘˜è¦**: Coupling the HIV fusion inhibitor C34 with CXCR4 (C34-CXCR4) protected CD4 T cells from all strains of HIV. Escape from C34-CXCR4 expression proved difficult, requiring more than 21 serial passages, m...

### [Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations.](https://pubmed.ncbi.nlm.nih.gov/41513407/)
- ğŸ“š **Journal for immunotherapy of cancer** | ğŸŒŸ **IF: 10.9**
- **æ‘˜è¦**: Engineering chimeric antigen receptor (CAR) T cells with logic-gated synthetic Notch (synNotch) receptor circuits can enhance specificity and mitigate on-target/off-tumor toxicity. However, the conven...

### [PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters.](https://pubmed.ncbi.nlm.nih.gov/41507351/)
- ğŸ“š **Communications biology** | IF: N/A
- **æ‘˜è¦**: The combination of chimeric antigen receptor (CAR)-T cell therapy with immune checkpoint blockade (ICB) using anti-PD-1 has been demonstrated to enhance antitumor CAR-T cell responses. Although, in co...

### [HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling.](https://pubmed.ncbi.nlm.nih.gov/41501787/)
- ğŸ“š **Cell communication and signaling : CCS** | IF: N/A
- **æ‘˜è¦**: Chimeric antigen receptor (CAR) T cell therapy has shown success in hematological malignancies, but its efficacy against solid tumors remains limited. Herpesvirus entry mediator (HVEM), a co-stimulato...

### [Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy.](https://pubmed.ncbi.nlm.nih.gov/41501251/)
- ğŸ“š **Nature biomedical engineering** | ğŸ”¥ **IF: 28.1**
- **æ‘˜è¦**: Major challenges facing chimeric antigen receptor (CAR)-T cell therapy for solid tumours include the immunosuppressive tumour microenvironment and the heterogeneity of antigen expression. Bacterial ou...

### [Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors.](https://pubmed.ncbi.nlm.nih.gov/41500474/)
- ğŸ“š **Biochemical pharmacology** | IF: N/A
- **æ‘˜è¦**: In current clinical applications, there are challenges with using chimeric antigen receptor (CAR)-T cells to effectively treat solid tumors. These challenges include promoting the infiltration and pro...

### [The LXRÎ²/NF-ÎºB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment.](https://pubmed.ncbi.nlm.nih.gov/41496523/)
- ğŸ“š **Oncoimmunology** | IF: 7.2
- **æ‘˜è¦**: Liver X receptor Î² (LXRÎ²) is a key transcription factor involved in lipid metabolism and immune regulation, yet its functional role in tumor-infiltrating T cells remains largely unresolved. While LXRÎ²...

### [In Vivo Generation and Manipulation of CAR-T-mimicking Cells via Magnetic Bispecific Nano-antibody for Solid Tumor Therapy.](https://pubmed.ncbi.nlm.nih.gov/41495981/)
- ğŸ“š **Advanced materials (Deerfield Beach, Fla.)** | IF: N/A
- **æ‘˜è¦**: The therapeutic efficacy of chimeric antigen receptor (CAR)-T cell therapy in combating solid tumors remains constrained, primarily due to inadequate tumor infiltration and the immunosuppressive tumor...

### [CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency.](https://pubmed.ncbi.nlm.nih.gov/41495526/)
- ğŸ“š **Nature cancer** | ğŸ”¥ **IF: 23.5**
- **æ‘˜è¦**: Insufficient functional T cell persistence impedes therapeutic success of chimeric antigen receptor (CAR) therapies. Here we performed a CAR-adapted base-editing screen of PIK3CD, a key regulator of T...

### [Optimizing In Vivo CAR-T Cell Engineering for Cancer Immunotherapy.](https://pubmed.ncbi.nlm.nih.gov/41490421/)
- ğŸ“š **Cancer research** | ğŸŒŸ **IF: 11.2**
- **æ‘˜è¦**: Chimeric antigen receptor (CAR)-T cell therapy enables potent, antigen-specific immune responses and has demonstrated success in treating hematologic malignancies. However, conventional ex vivo CAR-T ...

### [Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.](https://pubmed.ncbi.nlm.nih.gov/41490267/)
- ğŸ“š **Blood** | ğŸ”¥ **IF: 21.0**
- **æ‘˜è¦**: Patients with T-cell lymphomas and leukemias have overall poor outcomes due to the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. Development of chime...

